Suppr超能文献

使用 Pleuralvent™ 和胸腔引流管(ASPIRATE)治疗医源性气胸的疗效和镇痛药物使用:一项随机对照试验方案。

Efficacy and analgesic use during the therapy of iatrogenic pneumothorax using Pleuralvent™ and Chest Tube (ASPIRATE): A randomised controlled trial protocol.

机构信息

Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic.

Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.

出版信息

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Jun;164(2):213-215. doi: 10.5507/bp.2020.008. Epub 2020 Mar 9.

Abstract

BACKGROUND

Iatrogenic pneumothorax is a common complication of various diagnostic and therapeutic procedures such as transbronchial lung biopsies. The classical mode of treatment is chest tube insertion. Pneumothorax devices are now available on the market but there is a dearth of data on their efficacy to treat iatrogenic pneumothorax. It is important to provide such data as the pathophysiology of iatrogenic pneumothorax is different in comparison with spontaneous pneumothorax for which some data is available.

METHODS

This is a randomized, non-blinded, actively controlled trial of effectivity of iatrogenic pneumothorax treatment using the Pleuralvent™ device and chest tube insertion (16F). The secondary aim is to compare the overall pain level and the need for analgesic treatment in both treatment arms. We are planning to enrol 126 patients (63 in each treatment arm).

DISCUSSION

Preliminary results showed similar effectivity of the Pleuralvent™ system compared to large bore chest tube insertion. This randomized clinical trial should confirm these results and prove that the Pleuralvent™ system is an effective way of treatment of patients with iatrogenic pneumothorax. If Pleuralvent™ proves to have the same level of efficacy, it may become the standard of care of patients with iatrogenic pneumothorax.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier: NCT03700554.

摘要

背景

医源性气胸是经支气管肺活检等各种诊断和治疗程序的常见并发症。经典的治疗模式是插入胸腔引流管。气胸设备现在已经在市场上销售,但关于其治疗医源性气胸的疗效的数据却很少。提供这些数据非常重要,因为医源性气胸的病理生理学与自发性气胸不同,后者的数据是可用的。

方法

这是一项使用 Pleuralvent™ 装置和 16F 胸腔引流管(16F)治疗医源性气胸的随机、非盲、主动对照有效性试验。次要目的是比较两种治疗方法的总体疼痛水平和对镇痛治疗的需求。我们计划招募 126 名患者(每组 63 名)。

讨论

初步结果表明,Pleuralvent™ 系统与大口径胸腔引流管插入的疗效相似。这项随机临床试验应该证实这些结果,并证明 Pleuralvent™ 系统是治疗医源性气胸患者的有效方法。如果 Pleuralvent™ 被证明具有相同的疗效,它可能成为医源性气胸患者的标准治疗方法。

试验注册

ClinicalTrials.gov 标识符:NCT03700554。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验